Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 30.71% is in line with its 5-year average of 29.19%, around the middle of its 5-year range (11.72%–40.64%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.71% below its 12-month average of 32.23%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 30.71%.
RETURN ON EQUITY (ROE)
30.71%
RETURN ON EQUITY (ROE) AVG TTM
32.23%
RETURN ON EQUITY (ROE) AVG 3Y
33.77%
RETURN ON EQUITY (ROE) AVG 5Y
29.19%
RETURN ON EQUITY (ROE) AVG 10Y
22.28%
RETURN ON EQUITY (ROE) AVG 15Y
20.13%
RETURN ON EQUITY (ROE) AVG 20Y
19.33%
CURRENT VS TTM AVG
-4.71%
CURRENT VS 3Y AVG
-9.04%
CURRENT VS 5Y AVG
+5.22%
CURRENT VS 10Y AVG
+37.84%
CURRENT VS 15Y AVG
+52.56%
CURRENT VS 20Y AVG
+58.85%
SECTOR MEDIAN · HEALTHCARE
11.44%
median of 92 covered companies
CURRENT VS SECTOR MEDIAN
+168.47%
vs the sector median at left
Novartis AG
Market Cap
$267.96B
Return on Equity (ROE)
30.71%
TTM Avg
32.23%
3Y Avg
33.77%
5Y Avg
29.19%
Market Cap
$243.44B
Return on Equity (ROE)
20.79%
TTM Avg
19.16%
3Y Avg
15.60%
5Y Avg
13.86%
Market Cap
$242.75B
Return on Equity (ROE)
13.25%
TTM Avg
12.70%
3Y Avg
13.51%
5Y Avg
15.24%
Market Cap
$217.61B
Return on Equity (ROE)
74.80%
TTM Avg
79.33%
3Y Avg
111.35%
5Y Avg
101.76%
Market Cap
$332.18B
Return on Equity (ROE)
38.06%
TTM Avg
32.06%
3Y Avg
36.93%
5Y Avg
40.66%
Market Cap
$338.13B
Return on Equity (ROE)
14.34%
TTM Avg
14.18%
3Y Avg
19.86%
5Y Avg
21.18%
Market Cap
$356.05B
Return on Equity (ROE)
7.57%
TTM Avg
35.83%
3Y Avg
26.05%
5Y Avg
27.71%
Market Cap
$179.66B
Return on Equity (ROE)
-27.39%
TTM Avg
19.98%
3Y Avg
21.60%
5Y Avg
19.44%
Market Cap
$168.54B
Return on Equity (ROE)
10.61%
TTM Avg
20.32%
3Y Avg
18.59%
5Y Avg
17.97%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novartis AG (NVS) | $267.96B | 30.71% | 32.23% | 33.77% | 29.19% |
| AstraZeneca PLC (AZN)vs › | $243.44B | 20.79% | 19.16% | 15.60% | 13.86% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $242.75B | 13.25% | 12.70% | 13.51% | 15.24% |
| Amgen Inc. (AMGN)vs › | $217.61B | 74.80% | 79.33% | 111.35% | 101.76% |
| Roche Holding AG (RHHBY)vs › | $332.18B | 38.06% | 32.06% | 36.93% | 40.66% |
| UnitedHealth Group Incorporated (UNH)vs › | $338.13B | 14.34% | 14.18% | 19.86% | 21.18% |
| Merck & Co., Inc. (MRK)vs › | $356.05B | 7.57% | 35.83% | 26.05% | 27.71% |
| Gilead Sciences, Inc. (GILD)vs › | $179.66B | -27.39% | 19.98% | 21.60% | 19.44% |
| Abbott Laboratories (ABT)vs › | $168.54B | 10.61% | 20.32% | 18.59% | 17.97% |
| Novo Nordisk A/S (NVO)vs › | $165.79B | 53.50% | 61.58% | 67.05% | 123.42% |
ROE
30.7%
ROA
10.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 30.71% |
| 2026-03-31 | 35.14% |
| 2025-12-31 | 30.31% |
| 2025-09-29 | 32.47% |
| 2025-06-30 | 32.52% |
| 2025-03-31 | 33.51% |
| 2024-12-31 | 27.11% |
| 2024-09-30 | 40.64% |
| 2024-06-30 | 38.76% |
| 2024-03-31 | 38.42% |
| 2023-12-31 | 31.82% |
| 2023-09-30 | 20.53% |
| 2023-06-30 | 14.75% |
| 2023-03-31 | 13.50% |
| 2022-12-31 | 11.72% |
| 2022-09-30 | 35.84% |
| 2022-06-30 | 36.52% |
| 2022-03-31 | 39.30% |
| 2021-12-31 | 35.51% |
| 2021-09-30 | 17.27% |
| 2021-06-30 | 16.62% |
| 2021-03-31 | 15.75% |
| 2020-12-31 | 14.26% |
| 2020-09-30 | 13.04% |
| 2020-06-30 | 13.40% |
| 2020-03-31 | 23.85% |
| 2019-12-31 | 21.15% |
| 2019-09-30 | 22.47% |
| 2019-06-30 | 22.13% |
| 2019-03-31 | 26.15% |
| 2018-12-31 | 16.04% |
| 2018-09-30 | 17.18% |
| 2018-06-30 | 18.03% |
| 2018-03-31 | 11.34% |
| 2017-12-31 | 10.39% |
| 2017-09-30 | 9.24% |
| 2017-06-30 | 9.36% |
| 2017-03-31 | 9.42% |
| 2016-12-31 | 8.97% |
| 2016-09-30 | 9.08% |
| 2016-06-30 | 9.33% |
| 2016-03-31 | 9.45% |
| 2015-12-31 | 23.08% |
| 2015-09-30 | 23.75% |
| 2015-06-30 | 24.83% |
| 2015-03-31 | 26.54% |
| 2014-12-31 | 14.43% |
| 2014-09-30 | 15.07% |
| 2014-06-30 | 13.86% |
| 2014-03-31 | 13.84% |
| 2013-12-31 | 12.34% |
| 2013-09-30 | 12.76% |
| 2013-06-30 | 13.45% |
| 2013-03-31 | 14.14% |
| 2012-12-31 | 13.50% |
| 2012-09-30 | 12.61% |
| 2012-06-30 | 13.31% |
| 2012-03-31 | 13.61% |
| 2011-12-31 | 13.84% |
| 2011-09-30 | 15.28% |
| 2011-06-30 | 14.78% |
| 2011-03-31 | 14.74% |
| 2010-12-31 | 15.50% |
| 2010-09-30 | 15.00% |
| 2010-06-30 | 17.47% |
| 2010-03-31 | 16.97% |
| 2009-12-31 | 14.64% |
| 2009-09-30 | 14.32% |
| 2009-06-30 | 15.10% |
| 2009-03-31 | 16.96% |
| 2008-12-31 | 16.30% |
| 2008-09-30 | 14.90% |
| 2008-06-30 | 23.90% |
| 2008-03-31 | 24.55% |
| 2007-12-31 | 24.27% |
| 2007-09-30 | 25.65% |
| 2007-06-30 | 17.63% |
| 2007-03-31 | 18.26% |
| 2006-12-31 | 17.45% |
| 2006-09-30 | 17.81% |
| 2006-06-30 | 17.93% |
| 2006-03-31 | 19.56% |
| 2005-12-31 | 18.60% |
| 2005-09-30 | 19.42% |
| 2005-06-30 | 19.91% |
| 2005-03-31 | 20.21% |
| 2004-12-31 | 17.07% |
| 2004-09-30 | 18.55% |
| 2004-06-30 | 18.17% |
| 2004-03-31 | 17.89% |
| 2003-12-31 | 16.48% |
| 2003-09-30 | 18.75% |
| 2003-06-30 | 19.56% |
